These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9157590)

  • 1. Commercial antithrombin concentrate contains inactive L-forms of antithrombin.
    Chang WS; Harper PL
    Thromb Haemost; 1997 Feb; 77(2):323-8. PubMed ID: 9157590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Separation of active and inactive forms of human antithrombin by heparin affinity chromatography.
    Heger A; Grunert T; Schulz P; Josic D; Buchacher A
    Thromb Res; 2002 Apr; 106(2):157-64. PubMed ID: 12182916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1.
    Wardell MR; Chang WS; Bruce D; Skinner R; Lesk AM; Carrell RW
    Biochemistry; 1997 Oct; 36(42):13133-42. PubMed ID: 9335576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Separation of native and latent forms of human antithrombin by hydrophobic interaction high-performance liquid chromatography.
    Karlsson G; Winge S
    Protein Expr Purif; 2001 Feb; 21(1):149-55. PubMed ID: 11162400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Heterogeneity of mammalian antithrombin III].
    Bashkov GV; Kalishevskaia TM; Strukova SM
    Biokhimiia; 1989 Nov; 54(11):1797-803. PubMed ID: 2627551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and viral safety validation study of a pasteurized therapeutic concentrate of antithrombin III obtained through affinity chromatography.
    Biescas H; Gensana M; Fernández J; Ristol P; Massot M; Watson E; Vericat F
    Haematologica; 1998 Apr; 83(4):305-11. PubMed ID: 9592979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High and low anticoagulant activity heparins. Preparation in large scale and degree of complexation with antithrombin III.
    Takahashi HK; Nader HB; Dietrich CP
    Arzneimittelforschung; 1985; 35(11):1620-3. PubMed ID: 4091864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystallization and preliminary X-ray diffraction analysis of two conformations of intact human antithrombin.
    Wardell MR; Abrahams JP; Bruce D; Skinner R; Leslie AG
    J Mol Biol; 1993 Dec; 234(4):1253-8. PubMed ID: 8263926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latent and polymeric antithrombin: clearance and potential thrombotic risk.
    Corral J; Rivera J; Guerrero JA; Miñano A; Alberca I; Hernández-Espinosa D; Ordóñez A; Martínez C; Navarro-Núñez L; González-Conejero R; Lozano ML; Vicente V
    Exp Biol Med (Maywood); 2007 Feb; 232(2):219-26. PubMed ID: 17259329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of membrane adsorber (MA) based purification schemes for the down-stream processing of recombinant h-AT III.
    Reif OW; Freitag R
    Bioseparation; 1994 Dec; 4(6):369-81. PubMed ID: 7765681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification and further characterization of antithrombin III Milano: lack of reactivity with thrombin.
    Wolf M; Boyer-Neumann C; Meyer D; Tripodi A; Mannucci PM; Larrieu MJ
    Thromb Haemost; 1987 Oct; 58(3):888-92. PubMed ID: 3433251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pasteurisation induced changes in an antithrombin III concentrate.
    Winkelman L; Haddon ME
    Thromb Res; 1986 Jul; 43(2):219-27. PubMed ID: 3738862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of conformational transformation of antithrombin in blood with crossed immunoelectrophoresis: new application for a classical method.
    Corral J; Rivera J; Martínez C; González-Conejero R; Miñano A; Vicente V
    J Lab Clin Med; 2003 Nov; 142(5):298-305. PubMed ID: 14647033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An improved method for removal of antithrombin III from post-heparin plasma lipase fractions with a high recovery rate.
    Moriguchi EH; Tamachi H; Homma Y; Goto Y
    Tokai J Exp Clin Med; 1991 Mar; 16(1):33-41. PubMed ID: 1780907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of tryptophan modification upon digestion of antithrombin III by elastase.
    Scully MF; Shah N; Ellis V; Kakkar VV
    Thromb Haemost; 1991 Apr; 65(4):351-4. PubMed ID: 2057915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of heparin and heparinlike molecules in thrombosis and atherosclerosis.
    Rosenberg RD
    Fed Proc; 1985 Feb; 44(2):404-9. PubMed ID: 3155697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change.
    Turk B; Brieditis I; Bock SC; Olson ST; Björk I
    Biochemistry; 1997 Jun; 36(22):6682-91. PubMed ID: 9184148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of alpha- and beta- thrombin by antithrombin-III and heparin.
    Machovich R; Blaskó G; Borsodi A
    Thromb Haemost; 1976 Dec; 36(3):503-8. PubMed ID: 65798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a new potent heparin. 5th Communication: Further characterization by affinity chromatography on antithrombin-sepharose and its comparison with a commercially available heparin.
    Bhargava AS; Freihube G; Günzel P
    Arzneimittelforschung; 1980; 30(10):1621-3. PubMed ID: 7192096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.